Catalyst Wire Dossier Catalyst Wire Dossier

MK-6482

belzutifan · Merck & Co.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MK-6482, covering 2025-07-25 to 2025-07-25. Get the full timeline:

Most recent: Clinical Trial Update: ABEMA Alone or in COMBO With MK-6482 [Phase 1]

See pricing